Floatz logo

Carboplatin

Multiple Sclerosis, Relapsing-Remitting

GlaxoSmithKlineSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Multiple Sclerosis, Relapsing-Remitting cohort.

Asset / SponsorPhaseRating
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Cladribine
Uppsala University
Phase 4BBB
Ocrevus
Biocad
Phase 4BBB
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
University Hospital, Montpellier
Phase 4BBB
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Universitätsklinikum Hamburg-Eppendorf
Phase 4BBB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →